Influence of Intensive Lipid-lowering with statin and ezetimbe prescription on Computed Tomography Derived Fractional Flow Reserve in Patients With Stable Chest Pain: The FLOW-PROMOTE study - FLOWPROMOTE study

Department of Cardiology, Aarhus University Hospital, Denmark0 个研究点目标入组 120 人开始时间: 2019年7月24日最近更新: 2021年4月5日

试验速览

暂无简介。

•Patients must meet all of the following criteria:
•? Age >40 years
•?Symptoms suggestive of stable CAD
•? No known CAD
•? At least one stenosis with =50% lumen reduction determined by coronary CTA
•? Sinus rhythm
•? LDL cholesterol >2.0 mM*
•? FFRCT =0.80 (Figure 2)
•? Life expectancy >3 years
•? Signed informed consent
•? Minimum one stenosis =50% (visually or QCA).
•*Patients already on lipid lowering medical therapy can be included if meeting all of the above mentioned inclusion criteria.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 60
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 60

•Patients must meet none of the following criteria:
•? Unstable angina
•? Known CAD
•? Allergy to iodinated contrast media
•? Poor coronary CTA image quality inadequate for FFRCT calculation (determined by core laboratory)
•? Significant LM (stenosis >50%) or 3-vessel CAD determined by coronary CTA leading to direct referral to ICA (Figure 2)
•? Pregnancy
•? Participation in another clinical trial
•? Does not wish to participate
•Coronary computed tomography exclusion criteria:
•LM- stenosis =50%, 3-VD or high-grade proximal LAD stenosis resulting in direct referral to ICA.

发起方

Department of Cardiology, Aarhus University Hospital, Denmark